Group items tagged

An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer's proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death. The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB). Using that scale, experts said Lilly's findings were roughly on par with Eisai Co Ltd and Biogen Inc's lecanemab, sold under the brand name Leqembi, which reduced cognitive decline by 27% in patients with early Alzheimer's in a study published last year. The results drove Lilly's shares to a record high, up more than 6% at $429.85. Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, said Lilly's trial is the third to show removing amyloid from the brain slows progression of the disease, which could put to rest some lingering doubts about the benefits of drugs in the class and the amyloid-lowering theory. "It's modest, but I think it's real," he said of the benefit, "and I think it's clinically meaningful." Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital, said the efficacy looks as good or better than lecanemab.

The Royal Pharmaceutical Society (RPS) announced three new awards - the Daniel Thomas Award, the OPERA Award and the Barnett Award - at its annual conference on Friday. RPS President Professor Claire Anderson said each award recognises "exceptional contributions to the pharmacy field." The Daniel Thomas Award recognises pharmacists or pharmaceutical scientists who died while actively practising in the profession. It is named after Daniel Thomas, a pharmacist who died during the First World War in 1917 while serving with the Royal Army Medical Corps. The Outstanding Pharmacy Early-Career Researcher Award or OPERA Award recognises the achievements of early-career researchers within the pharmacy field.

Duncan Rudkin, the CEO of the General Pharmaceutical Council (GPhc) has highlighted the importance of strengthening pharmacy governance to provide clarity around how pharmacies are organised and managed. This will ensure that patients and the public continue to receive safe and effective pharmacy care, he said while speaking at the annual Sigma Conference in London on Sunday (5 November). According to him, there could be rules that outlined the essential roles and responsibilities of responsible pharmacists, and professional standards for responsible pharmacists, superintended pharmacists and chief pharmacists. He also announced that the GPhC will be shortly launching a consultation to integrate a new set of standards for the statutory role of hospital chief pharmacists "which up until recently has never been recognised in law." It is expected to be launched by early January 2024. However, Duncan, emphasised that they cannot start the work on standards for responsible and superintendent pharmacists until they know the government plans in relation to supervision. "Because of course, the responsible pharmacists' regime, and the supervision regime are in many ways intertwined, and can't certainly be looked at separately.

NHS England and NHS Improvement published on May 26 the findings of the Fuller 'stocktake' - setting out how primary care can work with partners across health and care to best meet the needs of their local communities. Dr Claire Fuller's report lays emphasis on the essential role of primary care and the potential of integrated neighbourhood teams in reducing the burden of ill health and tackling health inequities. It commends community pharmacy for keeping "its doors open to the public throughout" the pandemic whilst being "among the most recognisable of a multitude of dedicated staff delivering care around the clock in every neighbourhood in the country". The report highlights "recruitment and retention challenges across the wider primary care workforce" including in community pharmacy. Stressing the importance of community pharmacy teams in urgent care and prevention, including early diagnosis of cancers, the report points out that pharmacists could play "a more active role in signposting eligible people to screening and supporting early diagnosis, building on a number of successful pilots such as those from the Accelerate, Coordinate, Evaluate (ACE) programme".

UK regulator has approved a second oral antiviral for early treatment of Covid-19 in high-risk adults, after molnupiravir. The Medicines and Healthcare products Regulatory Agency (MHRA) gave its nod for a new treatment called Paxlovid (PF-07321332 and ritonavir), after finding it safe and effective at reducing the risk of hospitalisation and death in people diagnosed with mild Covid-19 infection. Developed by Pfizer, Paxlovid prevents the multiplying of virus, helping the body to overcome the infection. A clinical trial for the treatment in high risk individuals revealed that a five-days course of Paxlovid reduces the risk of hospitalisation and death by 89 per cent. It further revealed that Paxlovid is most effective when taken in the early stage of infection. Dr June Raine, MHRA chief executive, said: "We now have a further antiviral medicine for the treatment of Covid-19 that can be taken by mouth rather than administered intravenously. This means it can be administered outside a hospital setting, before Covid-19 has progressed to a severe stage."

The Department of Health and Social Care (DHSC) launched a new Innovative Medicines Fund on Tuesday (June 7) under which £340 million has been made available to purchase potentially life-saving drugs early. This will allow NHS patients in England to have early access to potentially life-saving and cutting-edge treatments Health secretary Sajid Javid said: "I want NHS patients to be the first in the world to access the most promising and revolutionary treatments that could extend or save their lives. "The launch of the Innovative Medicines Fund delivers another manifesto pledge and will fast-track cutting-edge medicines to adults and children to give people renewed hope for a better future." A total of £680 million has been ringfenced for the Innovative Medicines Fund and Cancer Drugs Fund - £340 million each - to fast-track medicines to NHS patients. DHSC said: "The Innovative Medicines Fund will provide quick access to novel treatments, including potentially lifesaving gene therapies for serious conditions with few treatment options. It often takes longer for pharmaceutical companies to collect data on a medicine's clinical and cost effectiveness for rare diseases due to the smaller patient cohort.

Japanese drugmaker Eisai said on Tuesday (January 10) it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease. Nearly all previous experimental drugs using the same approach have failed. The company's application to the European Medicines Agency is based on results from a late-stage study in which the drug was shown to slow down the rate of cognitive decline in patients with early Alzheimer's by 27 per cent, compared with a placebo. Eisai also reiterated its plans to apply for marketing authorization of the drug in Japan by the end of its business year on March 31.

Thousands of lung cancer patients in England will benefit from a ground-breaking new drug that can reduce the risk of relapse. This follows a deal brokered by NHS England and approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for atezolizumab therapy to treat non-small cell lung cancer (NSCLC). More than 850 patients are expected to be eligible for the drug in the first year, rising to more than 1000 in the third year. It is the first immunotherapy approved for patients with early-stage NSCLC who have undergone surgery and chemotherapy. Clinical trials have shown that atezolizumab can reduce the risk of cancer relapse or death by 34 per cent in patients with early-stage NSCLC.

The specification for the Pharmacy Contraceptive Service has been launched for pharmacy contractors to download from the NHSBSA website. However, the service will not start on 11th January 2023, as originally planned, but it is expected to commence in early 2023, revealed the Pharmaceutical Services Negotiating Committee (PSNC). It added: "The exact start date is yet to be agreed, as now the service specification has been published, community pharmacy IT system suppliers need time to develop support for the service, so this is available to contractors from the service commencement date." Commenting on the publication of the service specification, Alastair Buxton, Director of NHS Services, at PSNC said: "When time in their busy professional lives allows, the publication of the service specification ahead of the start of the new service provides contractors and their teams with an opportunity to learn more about it and to consider whether it is something they will have the capacity to provide in due course.

When diagnose of breast cancer at an early stage the effects are less damage to the breast tissues, you can be spared of severe treatment and it can bring faster healing.

Influenza, commonly shortened to "flu" is an extremely contagious respiratory illness caused by influenza A or B viruses. Flu appears most frequently in winter and early spring.

Most people do not realize that gum disease is the number one problem that we treat as dentists, not cavities. Eighty percent of the American population has some sort of gum disease, the early stages of which is gingivitis. This is when the gums become swollen, sore, and bleed. One needs to act beforehand to get rid of such problems.

Most people do not realize that gum disease is the number one problem that we treat as dentists, not cavities. Eighty percent of the American population has some sort of gum disease, the early stages of which is gingivitis. This is when the gums become swollen, sore, and bleed. One needs to act beforehand to get rid of such problems.

Genetically abnormal embryos are scientifically proven to be the primary cause of failed in vitro fertilization, rather than an individual uterine problem, according to RaipurIVF. Egg donor transfer is typically a preferred treatment option when repeated implantation failure occurs, however, surrogacy is another alternative. Finding a surrogate mother is a seemingly difficult task that requires extensive screening and in-depth profiling. However, the experts at the Pahlajani Test Tube Baby Centre offer cost effective rates that competitively rival the typical costs associated surrogacy. In addition, Dr. Neeraj Pahlajani boasts a very high surrogacy success rate, thus granting couples an advanced method of achieving contraception, in spite of the seeming difficulties associated with finding a surrogate.

Do you want to be aware of symptoms and treatment for psychological withdrawal? Read our latest blog to know how to overcome from these symptoms. Here are some methods for treating psychological withdrawal during the early stages of recovery. Learn more!

Do you want to be aware of symptoms and treatment for psychological withdrawal? Read our latest blog to know how to overcome from these symptoms. Here are some methods for treating psychological withdrawal during the early stages of recovery. Learn more!

we have some useful apps that you should definitely take a look at during your early days of motherhood

we have some useful apps that you should definitely take a look at during your early days of motherhood

If you are a pregnant mother waiting to meet your precious bundle, we congratulate you! Pregnancy is an exciting time and also a time for learning, as many moms-to-be in Katy find out, whether or not they have had kids before. Each pregnancy is different, just as every child is different, and you can never be sure exactly what to expect. However, there are some basic things you can do to ensure that your baby is healthy and to ease the delivery process.What is prenatal care?This is an umbrella term for all the services provided to you by an obstetrician in addition to your care routine at home before the baby is born. The first thing to do when you think you are pregnant is to confirm it through an at-home pregnancy test or a blood test (hCG test). Once your pregnancy is confirmed, you will need to call or visit your doctor so that you can get the essential vitamins. Folic acid, for example, has been proven to consistently reduce neural tube defects in newborns when the mother has taken sufficient amounts of it. It is now advised that all women hoping to get pregnant should start on folic acid early (dosage to be prescribed by your family doctor) and not wait until they are pregnant to take it. Prenatal vitamins are also recommended as a part of prenatal care by obstetricians in Katy around the 8th week of pregnancy.How often should you visit your obstetrician?In the first trimester you will only need to visit every four weeks. The doctor will check your weight and measure the stomach to get an idea of the baby's growth inside. The doctor will also check the heartbeat of the baby. During the third trimester, however, you may need to visit every two weeks and then once a week. At least one ultrasound test will be performed along with a few possible blood tests.For more information visit: Prenatal careImage Source: Google.com

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.

If you have recently been diagnosed with hearing loss, you may be feeling overwhelmed and unsure of what to do next. You are not alone - millions of people around the world are living with hearing loss. The good news is that there are many resources available to help you learn how to manage your condition and live a full life. In this blog post, we will discuss some of the most common issues that people with hearing loss face and provide tips on how to handle them. HANDLING ISSUES FROM HEARING LOSS - HOW TO DO IT PROPERLY Hearing loss is certainly a difficult obstacle to face in life, but it doesn't have to stop you from living a full and rich life. Of course, hearing loss comes with its own set of unique challenges, but there are ways to manage them. From learning what hearing aids are the best for you to communicate with loved ones, to the different types of therapies available, we're here to help you find the answers you need. Generally speaking, there are four main issues that people with hearing loss face; Isolation, communication difficulties, feeling overwhelmed and frustrated, and depression. Unfortunately, each of these "consequences" will likely get worse if hearing loss is not managed early on. Here are some tips on how to handle each one:

Prostate cancer is the most common cancer among men in the United Kingdom. However, Macmillan revealed that prostate cancer diagnoses were down 29 per cent between 2019 and 2020, meaning men weren't seeing their GPs to begin to get diagnosed. Therefore, it is of utmost importance to spot any symptoms and get checked, as an early diagnosis can help not only increase survival rates, but also offer a more varied choice of treatment options. As community pharmacy teams play a fundamental role in educating men who may be concerned about their health it vital to maximise trusted relationship with patients, and it is crucial that pharmacists have access to the correct resources to direct men to seek prostate cancer guidance. Prostate cancer often affects men who are over the age of 50. Those who are at a higher risk of prostate cancer also include those of African-Caribbean family descent, if there has been a family history of the cancer, and poor weight and diet. However, studies have found that community pharmacists play an important role in delivering programmes to improve levels of physical activity and diet of men with prostate cancer.

The government has joined hands with Prostate Cancer UK to launch a massive screening trial in the country next year. Called TRANSFORM, the trial will use innovative screening methods like an MRI scan to detect prostate cancer, which is the most common cancer in men in the UK. The trail is scheduled for launch in Spring 2024, and recruitment is likely to begin in Autumn 2024. For the £42 million trial, the government will invest £16 million through the National Institute of Health Research, and £26m will be provided by Prostate Cancer UK. The Department of Health and Social Care (DHSC) believes that thousands of men's lives could be saved each year if prostate cancer is detected early with effective screening methods.